Navigation Links
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
Date:9/21/2011

CENTRAL LABORATORIES 159

CONFAB LABORATORIES 159

COVANCE INC 160

COVIDIEN 160

CONTRACT PHARMACEUTICALS LIMITED 161

CORDEN PHARMA SWITZERLAND LLC 161

DAVOS PHARMA 162

DECODE GENETICS 162

DISHMAN PHARMACEUTICALS AND CHEMICALS LTD 163

DOW CHEMICAL 164

DPT LABORATORIES INC 164

DR REDDY'S LABORATORIES 165

DSM PHARMACEUTICAL PRODUCTS 165

FUJIFILM DIOSYNTH BIOTECHNOLOGY 166

ELAN DRUG TECHNOLOGIES 166

EVOTEC AG 167

FULCRUM PHARMA PLC 167

GIRINDUS AG 168

GLAXOSMITHKLINE 168

HOSPIRA 169

HAUPT PHARMA AG 170

HOVIONE SA 170

ICON PLC 171

INC RESEARCH, INC 171

JUBILANT LIFESCIENCES 172

KENDLE INTERNATIONAL INC 172

KP PHARMACEUTICAL TECHNOLOGIES INC 173

KV PHARMACEUTICAL CO 173

LIGAND PHARMACEUTICALS, INC 174

LONZA GROUP 174

LYNE LABORATORIES 175

MERCK / MSD BIOMANUFACTURING NETWORK 176

MIKART INC 176

NEXTPHARMA TECHNOLOGIES 177

NORWICH PHARMACEUTICALS 177

NOVAVAX, INC 178

OMNICARE CLINICAL RESEARCH 178

PAREXEL INTERNATIONAL CORPORATION 179

PATHEON INC 179

PERRIGO COMPANY 180

PFIZER (KING PHARMACEUTICALS 181

PIRAMAL HEALTHCARE LIMITED 181

PPD 182

PRA INTERNATIONAL 182

QUINTILES 183

RANBAXY 183

REGIS TECHNOLOGIES, INC 184

SKYEPHARMA 184

TALECRIS BIOTHERAPEUTICS INC 185

VETTER PHARMA INTERNATIONAL GMBH 185

WOCKHARDT LIMITED 186

WUXI APP TEC 187

XCELLEREX LLC 187

ZACH SYSTEM SPA 188

APPENDIX I: ABBREVIATIONS 189

To order this report:

Manufacturing Industry: <
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Generic Drugs: The Global Market
2. Generic Drugs: The Global Market: Focus on the Americas
3. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
4. Prosthetic Heart Valves - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
5. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
6. Accuray Incorporated to Speak at UBS Global Life Sciences Conference
7. Unilife to Present at the 2011 UBS Global Life Sciences Conference in New York City
8. Aperion Biologics Invited to Present at the UBS Global Life Sciences Conference
9. Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
10. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
11. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Covance Inc. (NYSE: CVD ) today reported ... Net revenue was $639 million, representing 8.0% growth from ... the company reported earnings of $0.29 per diluted share ... earnings per diluted share of $0.95, up 21.5% over ... asset impairment charges totaling $52.6 million, or $0.61 per ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... SPRINGS, Colo. , July 29, 2014 ... catheter (MARC) which could allow physicians to see and ... may hold promise, according to study authors who released ... (SNIS) 11 th Annual Meeting in ... stand to advance the field of neurointervention, a specialty ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
(Date:7/30/2014)... TX (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle ... guide that teaches people how to cure their nasal ... to readers the horrible truth about conventional treatments for nasal ... this book, people will learn how to prevent symptoms ... nasal infections. , Nasal Polyps Treatment Miracle, as it is ...
(Date:7/30/2014)... Francisco, CA (PRWEB) July 30, 2014 ... capture and physician communication, launched an Observation Result ... in the hospital. pMD’s cardiology customers are using ... optimize revenue for their test interpretations for electrocardiograms, ... interprets tests in the hospital, the cardiology system ...
(Date:7/29/2014)... Rancho Cucamonga, CA (PRWEB) July 29, 2014 ... “Realistic Ways to Make More Money in 30 Days” E-book. ... that anyone can use to make extra cash. Examples include ... and utilizing unique free websites that help people monetize the ... bedroom, and even unused items they can find in their ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced ... on Monday, March 9, 2009, at 4:30 p.m. EDT to ... results, and provide an update on recent corporate developments. To ... The live Webcast and replay access of the teleconference will ...
... Inc. (NYSE: CRE ), today announced that it will release ... market opens on Monday, March 16, 2009.The Company will host ... a.m. Eastern Time to discuss fourth quarter and year end ... dialing 800-240-2430 or by visiting the Company,s website at ...
... ... physicians and specialists , Kuala ... Asia the release of Centricity PACS Web Diagnostic (WebDX),a new Web-based ... RIS/ PACS, which bring comprehensive detailed patient,history to a single patient ...
... OF PRUSSIA, Pa., Feb. 27 Fourth quarter of ... Realty Income Trust (NYSE: UHT ) announced today ... net loss was $870,000, or $.07 per diluted share, as ... per diluted share, during the comparable quarter in the prior ...
... University of Pittsburgh Medical Center (UPMC) and Paphos Plantations Ltd. (PPL) - ... collaborating to develop a world-class health care center in Paphos, Cyprus, designed ... and foreign visitors to this Mediterranean island. , ... Pittsburgh, PA and ...
... to the media regarding the PLoS Medicine article published online ... patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated ... 2001. , ... San Diego, California ...
Cached Medicine News:Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 2Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 11Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 12Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 2Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 3Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 2Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 5
Khosla Precision and Quality in Medical and Surgical Products....
...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Medicine Products: